Human 6-Sulfo LacNAc-Expressing Dendritic Cells Are Principal Producers of Early Interleukin-12 and Are Controlled by Erythrocytes  by Schäkel, Knut et al.
Immunity 24, 767–777, June 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2006.03.020Human 6-Sulfo LacNAc-Expressing Dendritic Cells
Are Principal Producers of Early Interleukin-12
and Are Controlled by ErythrocytesKnut Scha¨kel,1,2,* Matthias von Kietzell,1 Anja Ha¨nsel,1
Annette Ebling,1 Livia Schulze,1 Michael Haase,3
Christian Semmler,2 Marika Sarfati,4 A. Neil Barclay,5
Gwendalyn J. Randolph,6 Michael Meurer,2
and E. Peter Rieber1
1 Institute of Immunology
2Department of Dermatology
3 Institute of Pathology
OncoRay
Biological and Molecular Targeting
Medical Faculty
Technische Universita¨t Dresden
01307 Dresden
Germany
4Centre Hospitalier de l’Universite de Montreal
Research Center
Hospital Notre-Dame
Montreal, Quebec H2L 4M1
Canada
5Sir William Dunn School of Pathology
University of Oxford
Oxford OX1 3RE
United Kingdom
6Department of Gene and Cell Medicine
Icahn Research Institute
Mount Sinai School of Medicine
New York, New York 10029
Summary
Early and high-level production of IL-12 is crucial for
effective immune responses against pathogens. Up
until now, the cells providing this initial IL-12 have re-
mained elusive. Here we show that a subset of human
blood dendritic cells (DC) is the principal and primary
source of IL-12p70 when blood leukocytes are stimu-
lated with the TLR4-ligand LPS or with CD40-ligand.
These so-called slanDC are characterized by the
6-sulfo LacNAc modification of PSGL-1, which is iden-
tified by the mAb M-DC8. The IL-12 response of slanDC
requires a few hours of in vitro maturation, which is
completely blocked in the presence of erythrocytes.
This inhibition of maturation depends on the expres-
sion of CD47 on erythrocytes and of its ligand SIRPa
on DC. While strictly controlled in the blood by eryth-
rocytes, the high IL-12- and TNF-a-producing capacity
of slanDC in tissues may be critical in fighting off path-
ogens; if uncontrolled, it may lead to adverse inflam-
matory reactions.
Introduction
Interleukin-12 (IL-12) plays a pivotal role in the initiation
of cell-mediated innate and adaptive immune responses
(Trinchieri, 2003). It enhances the cytotoxicity of natural
killer (NK) cells and stimulates their IFN-g production
*Correspondence: knut.schaekel@tu-dresden.de(Robertson et al., 1992). IL-12 produced by DC directs
the differentiation of naive CD4+ T cells into IFN-g-
producing T helper type 1 (Th1) cells. IFN-g secreted
by T cells and NK cells enhances the bactericidal activity
of macrophages and stimulates the production of com-
plement-fixing antibodies by B lymphocytes (Gately
et al., 1998). The pivotal contribution of IL-12 to the de-
fense against pathogens has been demonstrated in
many studies that used genetically engineered animals
lacking IL-12 or neutralizing antibodies against IL-12
(Trinchieri, 2003). To cope with the rapid kinetics of bac-
terial replication, IL-12 production is needed at the very
beginning of an immune response. On the other hand,
IL-12 expression must be strictly controlled because
systemic application of IL-12 proved to be highly toxic
(Cohen, 1995; Leonard et al., 1997; Portielje et al., 2003).
IL-12 consists of a 35 kDa light chain covalently linked
to a 40 kDa heavy chain to form the biologically active
p70 heterodimer. Though myeloid dendritic cells (DC)
and macrophages have been shown to be able to pro-
duce IL-12, the principal source of IL-12 at the decisive
initial phase of an antibacterial immune response has
not yet been identified in humans (Ma and Trinchieri,
2001).
With the help of the monoclonal antibody (mAb)
M-DC8, we previously identified a novel population of
human blood DC. The mAb-defined epitope that is se-
lectively expressed by these DC was identified as
6-sulfo LacNAc, an O-linked carbohydrate modification
of PSGL-1. Initially named after the mAb M-DC8 that
identified this cell population, we now call these cells,
in reference to the specific marker (6-sulfo LacNAc),
‘‘slanDC.’’ These cells account for the majority of DC in
human blood (0.6%–2% of peripheral blood mononu-
clear cells) and have a phenotype (6-sulfo LacNAc+,
CD1c2, CD11c+, CD16+, CD142, C5aR+, CD45RA+) dif-
fering from that of previously described DC (Scha¨kel
et al., 1998, 2002). They are potent inducers of primary
antigen-specific T cell responses in vitro, able to medi-
ate ADCC (Schmitz et al., 2002), stimulate NK cells
(Schmitz et al., 2005), and migrate in response to ana-
phylatoxins, and they display a striking capacity to pro-
duce TNF-a when stimulated by LPS. Altogether, these
features define slanDC as a highly proinflammatory sub-
set of circulating DC (Scha¨kel et al., 2002).
In this paper, we demonstrate that slanDC are the
early and principal IL-12p70-producing cells among
blood leukocytes. These findings emphasize the role
of slanDC in the induction and perpetuation of inflamma-
tion. Accordingly, slanDC can be found in high frequen-
cies in diseases characterized by local Th1-dominated
inflammatory response such as psoriasis vulgaris and
rheumatoid arthritis.
Furthermore, we demonstrate that the proinflamma-
tory capacity of slanDC, while circulating in blood, is
strictly controlled by erythrocytes that completely inhibit
the maturation of slanDC and their IL-12 production. The
expression of CD47 on erythrocytes and signal-regula-
tory protein a (SIRPa) on slanDC appeared to be critical
for this inhibition.
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768Figure 1. SlanDC Rapidly Acquire an IL-12 Producing Capacity In Vitro
(A) Freshly isolated PBMC were stimulated with LPS (100 ng/ml) directly after their isolation or after a preculture period of 3 or 6 hr. 24 hr later, cell
supernatants were harvested and IL-12p70 was quantified by enzyme-linked immunosorbent assay (ELISA). The mean 6 SEM of 4 donors are
shown.
(B) Fresh or precultured PBMC were stimulated with LPS in the presence of brefeldin A (1 mg/ml) to block cytokine secretion. Histograms show
intracellular IL-12p40 staining of cells after 24 hr of stimulation (filled histogram) or the respective isotype control (empty histogram). Numbers
give the mean fluorescence intensity (MFI) of IL-12p40 staining. Gating was done for mAb M-DC8+ cells (slanDC), CD1c+ DC (CD32, CD142,
CD192, CD162, CD562, CD342, C5aR2, M-DC82, CD11c+, HLA-DR+), or monocytes (CD14+). Results are from one representative out of four
experiments.
(C) Comparision of the LPS-induced IL-12 production of precultured 6-sulfo LacNAc+ and 6-sulfo LacNA2 CD16+ myeloid cells assessed by in-
tracellular staining for IL-12p40. Columns show the relative MFI for IL-12p40 staining of gated CD16+-6-sulfo LacNA2 cells compared to those of
gated slanDC, which were set as 100%. The results of four donors are expressed as the mean 6 SEM.Results
Identification of the Early and Principal Cellular
Source of IL-12 in Response to LPS
To identify the human leukocyte population that is pri-
marily involved in the initial supply of IL-12 in the course
of a bacterial infection, we first stimulated peripheral
blood mononuclear cells (PBMC) with lipopolysaccha-
ride (LPS), an endotoxin derived from the cell wall of
gram-negative bacteria, which activates cells through
the toll-like receptor (TLR) 4 (Poltorak et al., 1998).
Only low-level secretion of the bioactive p70 form of
IL-12 was seen when LPS was added to freshly isolated
PBMC (Figure 1A). However, it markedly increased when
PBMC were cultured for at least 3 hr prior to LPS stimu-
lation. This indicates that IL-12-producing leukocytes
require a short period of functional maturation in vitro
in order to respond to LPS stimulation. For the identifi-
cation of IL-12-producing cells among PBMC, intracel-
lular IL-12 staining was combined with phenotyping of
leukocyte subsets (Figure 1B) including CD14+ mono-
cytes, classical CD1c+ myeloid DC (O’Doherty et al.,
1994), and the recently identified population of slanDC
(Scha¨kel et al., 1998). Compared to CD1c+ DC and
CD14+ monocytes, slanDC were found to be particularly
efficient producers of IL-12p40 in response to LPS
(Figure 1B). In addition, we analyzed a subset of HLA-
DR+ myeloid cells that differentiates into DC when
reverse transmigrating through endothelium and that
shares the expression of CD16 with slanDC (Randolph
et al., 1998, 2002). Since these cells lack a specific
marker, CD16+ cells were purified from NK cell-depleted
PBMC as previously described (Randolph et al., 2002)
and stimulated with LPS. Intracytoplasmic IL-12p40
staining was combined with electronic gating for
slanDC. The CD16+ M-DC82 cells revealed a much lower
capacity to produce IL-12 when compared to CD16+M-DC8+ DC (slanDC) (Figure 1C). Besides pointing
out these functional differences, we aimed at a clear
phenotypic delineation of the cells under study. The
side-by-side comparison of fresh CD16+ M-DC8+
slanDC, CD16+ M-DC82 cells (representing CD16+/
CD14+ cells), CD1c+ DC, and pDC reveals a clear-cut
phenotypic definition of the various analyzed subsets
(see Figure S1 in Supplemental Data available with this
article online).
The marked IL-12 production by slanDC as shown by
intracellular cytokine staining was confirmed by deter-
mining bioactive IL-12p70 secreted by purified slanDC,
CD1c+ DC, and monocytes after stimulation with the
TRL4-ligand LPS as well as CD40L (Figure 2A). For these
studies, slanDC were isolated from freshly prepared
PBMC by labeling them with the mAb M-DC8 (mouse
IgM) followed by mouse IgM-specific paramagnetic
beads for subsequent positive selection of the labeled
cells by magnetic cell sorting. CD1c+ DC and monocytes
were isolated from 6-sulfo LacNAc2 PBMC as detailed
in the Experimental Procedures. Similar to LPS, stimula-
tion with the TLR7- and TLR8-ligand R848 induced high-
level production of IL-12p70, IL-12p40, as well as TNF-a,
IL-6, and IL-1b (Figure 2B). SlanDC remained unrespon-
sive to the TLR3-ligand Poli I:C, showed no IL-12p70
secretion, and showed only low-level production of IL-
12p40 and other cytokines after stimulation with the
TLR2-ligand Pam3CSK4 (Figure 2B). Interestingly, the
LPS-induced secretion of IL-12p40 and IL-12p70 was
strongly reduced in the presence of 50 mM resveratrol,
an inhibitor of TRIF signaling, whereas the production
of TNF-a, IL-6, and IL-1b remained unchanged in the
presence of resveratrol.
Taken together, these data show that slanDC by far
exceed other cells in the production of IL-12 in response
to the TLR4-ligand LPS or to CD40L. We next asked
whether the superior capacity of slanDC to produce
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(A) IL-12p70 was quantified in supernatants of purified slanDC, CD1c+ DC, and CD14+ monocytes stimulated with LPS or CD40L directly after
isolation or after 6 hr culture. The mean 6 SEM of three different experiments are shown.
(B) Cytokine production by slanDC stimulated after 6 hr culture with a range of concentrations (horizontal axis) of LPS in the absence (filled
squares) or in the presence of 50 mM resveratrol (open squares), R848 (circles), Pam3CSK4 (diamonds), and Poli I:C (triangles). Cytokines
were measured in 48 hr culture supernatants. Data are represented as means of triplicates of one representative of four experiments.
(C) Purified cell populations were primed with IFN-g for 6 hr prior to stimulation. IL-12p70 secretion was determined in triplicate cultures, the
mean 6 SEM of one representative out of four independent experiments is given.
(D) IL-12p70 was quantified in supernatants of mAb M-DC8-depleted PBMC and mock-depleted PBMC of four different donors. The preculture
period of 6 hr was followed by 24 hr of stimulation with LPS and IFN-g.IL-12 is retained when cells are prestimulated with IFN-g
before applying various TLR stimuli. The IL-12 secretion
by slanDC strongly increased when the cells were
primed with IFN-g followed by LPS or R848 stimulation.
Also, monocytes and CD1c+ DC showed a distinct IL-12
production, which, however, was almost 10 times lower
compared to that of slanDC (Figure 2C).
That slanDC represent the major source of IL-12
among blood leukocytes was also evident when PBMC
were depleted of slanDC by magnetic cell sorting. The
removal of these cells resulted in a 4- to 10-fold drop
in the IL-12 production after maximal stimulation with
LPS and IFN-g (Figure 2D).IL-12-Dependent Th1 Programming
by LPS-Stimulated SlanDC
Having demonstrated the early and high-level IL-12 pro-
duction by slanDC, we investigated its impact on the
programming of Th1 and Th2 cells during the course of
a primary T cell activation. Freshly isolated slanDC had
a strong capacity to promote the proliferation of naive
CD4+ cord blood T cells (Figure 3A) and were clearly
able to program IFN-g-producing Th1 cells (Figure 3B)
with or without preincubation (Figure 3C). The activation
of IL-4-producing Th2 cells was low and was further re-
duced when DC that were precultured for 6 hr were used
for T cell polarization (Figures 3B and 3C). When the T
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770cell priming was set up in the presence of LPS, a dra-
matic increase in the number of Th1 cells was seen,
but only when slanDC were licensed to respond to LPS
through a preculturing of 6 hr (Figure 3D). SlanDC-derived
IL-12 essentially contributed to the differentiation of naive
T cells into Th1 cells, since this could completely be pre-
vented by a blocking anti-IL-12 mAb. Similar results were
observed when T cell-derived IFN-g was determined in
the cell-culture supernatants (Figure 3E).
Erythrocytes Inhibit the Phenotypic Maturation
of SlanDC by a CD47-Dependent Mechanism
The functional maturation of slanDC toward LPS re-
sponsiveness during a 6 hr culture period was accompa-
nied by a rapid phenotypical maturation as documented
by an increased expression of the DC activation marker
CD83 as well as of HLA-DR, CD86, and CD40 (Figures 4A
and 4E). This maturation was not induced by the isola-
tion procedure, because slanDC enriched from PBMC
by the depletion of T cells, B cells, and monocytes
showed the same expression levels of CD83 and HLA-
DR as slanDC purified by the mAb M-DC8-based mag-
netic cell sorting that were then added back to the neg-
ative cell fraction (Figure 4B).
In addition, the trigger to mature is not provided by
cell adherence to culture dishes because slanDC also
matured when cultured on teflon surfaces (Figure 4C).
A similar upregulation of CD83 was observed when
freshly isolated CD1c+ DC were cultured in vitro
(Figure 4G).
The findings that freshly isolated slanDC have the ho-
mogeneous appearance of immature DC (Scha¨kel et al.,
2002) and that they immediately start to mature during in
vitro culturing suggest that they are prevented from mat-
uration while circulating in the blood. Accordingly, upre-
gulation of CD83 and HLA-DR on slanDC was not seen
when whole blood was cultured (Figure 4D). To deter-
mine whether the presence of red blood cells inhibits
DC maturation, purified slanDC were cultured together
with washed human erythrocytes at a ratio of 1:1000
for 18 hr. In the presence of erythrocytes, we observed
a complete inhibition of CD83 and CD40 upregulation
and a partially blocked upregulation of CD86 and
HLA-DR on slanDC (Figure 4E). This inhibitory effect of
erythrocytes could be overcome by the presence IFN-g.
To identify the mechanism involved in the erythrocyte-
mediated inhibition of DC maturation, various experi-
mental approaches were undertaken. First of all, contact
of erythrocytes with DC appeared to be required for the
Figure 3. IL-12-Producing SlanDC Program Strong Th1 Responses
(A) CD4+ CD45RA+ cord blood T cells (1 3 105) were activated with
different numbers of allogeneic slanDC that were either freshly iso-
lated (open circles) or cultured for 6 hr (filled circles). After 4 days,
T cell proliferation was evaluated by [3H]-thymidine incorporation.
(B–E) Cocultures of T cells and slanDC were restimulated after 10
days with ionomycin and PMA to study the cytokine production ei-
ther by staining for intracytoplasmatic IL-4 and IFN-g (B and D) or
by quantifying the amount of secreted cytokines by ELISA (C and
E). As indicated (D), fresh or precultured DC were coculture with T
cells in the presence or absence of LPS, a blocking anti-IL12-mAb
or an IgG1-control mAb (10 mg/ml). Individual results of nine (B)
and of four (C) separate experiments are demonstrated or one rep-
resentative out of at least four experiments is shown (A, D, and E).
CPM = counts per minute.
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(A) Histograms show the expression kinetics of CD83 on the cell surface of purified slanDC cultured in the absence of additional stimulation for
different lengths of time. The percentages of CD83+ slanDC and the mean fluorescence intensity (MFI) of cell-surface HLA-DR at different points
of culture are given in the diagram below. Depicted are the mean and the individual values obtained with cells from three different donors.
(B) CD83 and HLA-DR expression on slanDC among 12 hr cultured PBMC cultured for 12 hr after magnetic depletion of T cells, B cells, and mono-
cytes (filled histogram), compared to slanDC isolated by M-DC8-directed magnetic cell sorting from the enriched population and added back to
the negative fraction (empty histogram).
(C) Expression of CD83 and HLA-DR was compared between purified slanDC cultured in conventional polystyrol dishes (empty histograms) or in
Teflon beakers (filled histograms).
(D) Histograms display the expression levels of CD83 and HLA-DR of gated slanDC (filled histograms) among fresh and cultured blood and that of
the respective isotype control (empty histograms).
(E) The expression levels of CD83, HLA-DR, CD86, and CD40 by purified slanDC cultured for 18 hr in the absence or presence of erythrocytes
(1:1000) and IFN-g (100 ng/ml) are shown. The results of one representative experiment out of at least three are given. Empty histograms
show staining results of respective isotype controls.
(F) PBMC were directly cultured with erythrocytes at a ratio of 1:1000, separated from the erythrocytes by a membrane, cultured with erythro-
cytes preincubated with aminotriazole and mercaptosuccinate to block their free radical scavenging capacity, or were cultured with CD47-Fab
(40 mg/ml)-pretreated erythrocytes. 18 hr later, CD83 expression on gated slanDC was quantified by FACS analysis. The inhibition of CD83 up-
regulation by erythrocytes left untreated was set to 100%. The relative inhibitory capacity is expressed as the mean 6 SEM of three separate
experiments.
(G) PBMC were cultured with or without erythrocytes, and CD83 expression of gated slanDC and CD1c+ DC was compared 18 hr later. The
mean 6 SEM of four experiments is given. Ery = erythrocytes.inhibition of DC maturation because erythrocytes sepa-
rated from DC by a semipermeable membrane did not
influence DC maturation (Figure 4F). To determine
whether the capacity of erythrocytes to scavenge free
radicals alters DC activation as previously shown for T
cells and granulocytes (Aoshiba et al., 1999; Arosa
et al., 2004; Fonseca et al., 2001, 2003), erythrocytes
were treated with aminotriazole and mercaptosuccinate
to prevent erythrocyte catalase and glutathione from
scavenging free radicals. However, erythrocytes treated
in this way were as inhibitory as control erythrocytes.
Furthermore, direct incubation of the PBMC with cata-
lase did not influence CD83 upregulation (data not
shown). Oldenborg et al. reported that CD47 is a self
protective marker on murine red blood cells. Interaction
of CD47 expressed on erythrocytes with SIRPa, an ITIM-
containing inhibitory receptor on spleen macrophages,
was shown to inhibit the phagocytosis of erythrocytes
(Oldenborg et al., 2000).When PBMC were cocultured with erythrocytes incu-
bated with Fab fragments of a blocking CD47 antibody,
DC were not prevented from maturing. To determine
whether the inhibition of maturation was restricted to
proinflammatory slanDC, CD83 upregulation on CD1c+
DC in the presence of erythrocytes was also examined.
In contrast to slanDC, maturation of CD1c+ DC was only
marginally reduced by erythrocytes (Figure 4G).
Erythrocytes Prevent SlanDC from Acquiring
an IL-12-Producing Capacity
When PBMC were cultured in the presence of human red
blood cells and then depleted of erythrocytes by Ficoll-
density centrifugation, they were prevented from
producing IL-12 in response to LPS as shown by intra-
cellular staining of IL-12p40 (Figure 5A). Moreover, the
secretion of bioactive IL-12p70 upon stimulation with
LPS was completely blocked when purified slanDC
were precultured in the presence of erythrocytes
Immunity
772Figure 5. Erythrocytes Control the IL-12 and TNF-a Production of
SlanDC
(A) PBMC were cultured for 12 hr without (left) or with (right) human
erythrocytes, subjected to Ficoll gradient centrifugation to deplete
erythrocytes followed by stimulation with LPS. Cell-surface staining
with mAb M-DC8 and intracellular anti-IL-12p40 staining was done
after 24 hr.
(B–F) Purified slanDC were cultured with or without erythrocytes fol-
lowed by depletion of erythrocytes and subsequent stimulation with
LPS (B and D) or LPS and IFN-g (C, E, and F). IL-12p70 and TNF-a se-
creted into the cell-culture supernatant were quantified by ELISA. (F)
Purified slanDC were cultured with erythrocytes left untreated or
pretreated with anti-CD47 or anti-CD35 (CR1) for 12 hr before eryth-
rocytes were depleted and slanDC were stimulated.
(G) Erythrocytes were incubated with PBMC in the presence or ab-
sence of the SIRPa/g-specific mAb OX118 or an isotype control
mAb. After depletion of erythrocytes, the cells were stimulated
with LPS and the percentage of IL-12-producing cells was deter-
mined by flow cytometric analysis 18 hr later. The relevance of SIRPa(Figure 5B). Even maximal stimulation of DC by simulta-
neous treatment with LPS and IFN-g resulted in a clear
reduction of IL-12 secretion (Figure 5C). Moreover, the
release of TNF-a after LPS treatment was partially in-
hibited by preincubation with erythrocytes (Figure 5D).
This effect was even more pronounced in the presence
of IFN-g, which markedly increased the TNF-a produc-
tion (Figure 5E).
To determine whether the inhibition of IL-12p70 pro-
duction depends on a negative signal provided by eryth-
rocytes expressing CD47, slanDC were incubated for 12
hr either with erythrocytes preincubated with a CD47-
blocking mAb or, as a control, with erythrocytes on which
the complement receptor 1 (CR1, CD35) was blocked by
a specific mAb. Blocking of CD47 largely abrogated the
inhibitory capacity of erythrocytes (Figure 5F).
Possible binding partners of CD47 on slanDC are the
SIRP molecules a, b, and g. Myeloid cells including
slanDC express the inhibitory molecule SIRPa and the
stimulatory molecule SIRPb but not SIRPg (Brooke
et al., 2004; and data not shown). We, therefore, blocked
the interaction of CD47 on erythrocytes with SIRPa on
slanDC by the SIRPa/g-specific mAb OX118 (10 mg/
ml). This initial 12 hr culture period was then followed
by complete depletion of erythrocytes and stimulation
with LPS. Inhibition of IL-12 production by slanDC was
partially reversed when the OX118 mAb was present
during the initial coculture with erythrocytes, whereas
the isotype control was ineffective (Figure 5G). These
data show that erythrocytes can prevent slanDC from
acquiring the capacity to produce IL-12 by delivering
a negative signal through interaction of CD47 on erythro-
cytes with SIRPa on slanDC.
Identification of SlanDC in Inflamed Tissue of
Psoriasis Vulgaris and Rheumatoid Arthritis
SlanDC are the largest DC subtype in the blood; how-
ever, little is known about their distribution in tissue.
de Bay et al. described the presence of slanDC in the il-
eal mucosa of patients with active Crohn’s disease (de
Baey et al., 2003). Compared to healthy skin and syno-
via, we identified a high frequency of slanDC in the der-
mis of psoriasis vulgaris lesions and in the pannus tissue
of rheumatoid arthritis (Figures 6A and 6B). As in the
blood, all 6-sulfo LacNAc-positive cells coexpressed
the myeloid marker CD68 (Figure 6C). The common
pathogenic link between psoriasis vulgaris, rheumatoid
arthritis, and Crohn’s disease is a strong Th1-dominated
inflammatory reaction. The recent success of therapeu-
tic strategies targeting the locally enhanced production
of TNF-a and IL-12 has promoted a strong interest in
identifying the cellular sources of these cytokines. Our
data suggest that within these tissues, slanDC are
good candidates as the cellular source of IL-12.
Discussion
A characteristic feature of the immune response against
pathogens is the immediate availability of potent
inhibition for IL-12 production is expressed as the relative inhibition
compared to control cultures. Data represent mean 6 SEM of tripli-
cate samples of one representative experiment out of three.
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flammatory Infiltrate of Psoriasis Vulgaris
and Rheumatoid Arthritis
(A and B) Paraffin-embedded sections of le-
sional skin of psoriasis vulgaris (A) and in-
flamed synovia of rheumatoid arthritis (B)
were pretreated by boiling in citric acid and
subsequently stained to detect the expres-
sion of 6-sulfo LacNAc with the mAb DD2, fol-
lowed by biotinylated goat anti-mouse Ig,
which was detected by PO-streptavidin and
diaminobenzidine tetrahydrochloride. Origi-
nal magnifications: 310 (left images); 340
(right images).
(C) Double immunofluorescent staining of
paraffin-embedded sections was done by
means of the mAb DD2 to identify slanDC
(green) and to identify cells positive for the
myeloid marker CD68 (red). Results are rep-
resentative of at least five samples tested.effector mechanisms as well as their stringent control.
Here we identify a subset of human blood DC character-
ized by the expression of the PSGL-1 carbohydrate 6-
sulfo LacNAc, now called slanDC, as the early and prin-
cipal source of IL-12 after stimulation with the bacterial
TLR4-ligand LPS, the TLR7/8-ligand R848, or CD40L.
In addition, we provide evidence that the capacity of
these DC to produce IL-12 is blocked by the contact
with erythrocytes.
High-level IL-12 production during the initial phase of
an immune response is believed to cause NK cells to be-
come cytotoxic and to be involved in programming IFN-
g-producing Th1 cells that direct the immune defense
against pathogens or malignant tumors. By using differ-
ent approaches such as the IL-12 production on the sin-
gle-cell level among unseparated PBMC, quantification
of IL-12 secreted by highly purified cell populations,
and the selective depletion of slanDC from PBMC, we
show that slanDC excel by their capacity to produce
IL-12p40 and p70 among cultured human blood
leukocytes.SlanDC are of myeloid origin and represent the largest
blood DC subset (0.6%–2% among PBMC) having the
phenotype of CD16+, CD1c2, CD11c+, CD123low
BDCA22, BDCA42 and lineage marker negative (linneg:
CD32, CD142, CD192, CD562) cells (Scha¨kel et al.,
1998). The selective marker 6-sulfoLacNAc, which is
identified by the mAbs M-DC8, DD2, and DD1 (Scha¨kel
et al., 2002) and by the expression of FcgRIII (CD16),
C5aR, and C3aR, clearly distinguishes these proinflam-
matory cells from classical CD1c+ blood DC (CD162,
CD1c+, CD11c+, CD123low, BDCA22, BDCA42, linneg)
and from plasmacytoid DC (CD162, CD11c2, CD123high,
BDCA2+, BDCA4+, linneg). SlanDC also show essential
phenotypic differences to CD16+ monocytes. Most obvi-
ous is the differential expression of CD11b, CD14, CD33,
CD45RA, CD45RO, CD62L, CD64, and HLA-DR as docu-
mented in Figure S1.
The immature phenotype of blood slanDC and CD1c+
DC indicate that these cells recently egressed from the
bone marrow. The failure to generate 6-sulfo LacNAc-
expressing DC from CD14+ monocytes and CD34+
Immunity
774stem cell precursors under conditions to generate
CD1a+ DC (unpublished observation) suggests that
these two myeloid DC populations originate from differ-
ent precursor cells or require distinct signals for their
generation in vivo.
We previously documented the marked capacity of
slanDC to produce TNF-a in response to LPS and to vig-
orously induce primary T cell responses (Scha¨kel et al.,
2002). In addition, slanDC can efficiently mediate anti-
body-dependent cellular cytotoxicity (ADCC) (Schmitz
et al., 2002) and promote the proliferation, IFN-g produc-
tion, and tumor-directed cytotoxicity of NK cells
(Schmitz et al., 2005).
Freshly isolated immature slanDC are not yet in a func-
tional state to respond to LPS with IL-12 production,
although they have a marked capacity to produce
TNF-a when stimulated with LPS and display a strong
spontaneous (Randolph et al., 2002) and C5a-directed
(Scha¨kel et al., 2002) migratory activity.
For the production of IL-12 and the programming of
Th1 cells in response to LPS or CD40L stimulation,
slanDC require maturation during in vitro culturing for
about 6 hr. How maturation of slanDC determines their
differential capacity to produce IL-12 in response to
the TLR4 stimulus is not yet clear.
The activation of TLR4 induces signaling through two
pathways, MyD88 and the Toll/IL-1 receptor (TIR)-do-
main-containing adaptor-inducing IFN-b (TRIF). When
employing the recently described inhibitor of TRIF-sig-
naling resveratrol (Youn et al., 2005), we observed that
intact TRIF signaling was required for high-level IL-
12p40 and IL-12p70 production upon LPS stimulation.
This concurs with a report showing that the DC of
mice carrying a loss-of-function mutation of TRIF have
largely reduced IL-12p40 mRNA levels upon LPS stimu-
lation (Weighardt et al., 2004). Interestingly, the produc-
tion of TNF-a, IL-1b, and IL-6 by LPS-stimulated slanDC
was not altered in the presence of resveratrol. Taken to-
gether, these data give evidence that the difference in
the LPS-induced IL-12 production between immature
and mature slanDC can be explained by the differential
signaling through TRIF.
The spontaneous acquisition of the IL-12-producing
capacity of slanDC was paralleled by fundamental phe-
notypic changes indicative of DC maturation. Within 3 to
6 hr, the cells became positive for CD83, doubled HLA-
DR expression levels, and largely increased the expres-
sion of the costimulatory molecules CD80, CD86, and
CD40. These phenotypic changes occurred irrespec-
tively of the isolation procedure and did not require the
adhesion of slanDC to the culture vessel, as shown by
the fact that they were also observed when the cells
were cultured on teflon.
Taking into account that slanDC are immature in the
blood and do not undergo phenotypical maturation in
whole-blood cultures, we searched for a blood factor
that inhibits DC maturation. We made the observation
that an excess of erythrocytes, mimicking the physio-
logical conditions in the blood, completely prevented
the phenotypical maturation of slanDC, while maturation
of CD1c+ DC was only marginally inhibited. Most nota-
bly, slanDC cultured in the presence of erythrocytes
and subsequently stimulated with LPS failed to produce
IL-12p70 and showed a blunted TNF-a secretion.Blocking experiments revealed that intact expression
of CD47 (integrin-associated protein) by erythrocytes
was critical for their capacity to block the CD83 upregu-
lation and subsequent IL-12 production. CD47 was pre-
viously shown to inhibit phagocytosis of murine erythro-
cytes by spleen macrophages and was therefore
regarded as a marker of self on erythrocytes (Oldenborg
et al., 2000). We reveal the control of proinflammatory
slanDC in blood as a new function of CD47 on erythro-
cytes. CD47 binds to a family of signal regulatory pro-
teins (SIRPa, b, g) (Brooke et al., 2004; Seiffert et al.,
1999) first described by Kharitonenkov et al. (1997).
SIRPa, an inhibitory receptor containing two ITIM mo-
tives, as well as the stimulatory SIRPb molecule, but
not SIRPg, are expressed on myeloid cells (Brooke
et al., 2004).
Based on our inhibitory experiments, we propose that
SIRPa is a relevant structure on slanDC that, after liga-
tion by CD47 on erythrocytes, can transmit a negative
signal to slanDC that blocks their maturation and the
subsequent production of IL-12 after LPS stimulation.
Similarly, SIRPa signaling was shown to reduce TNF-
a production by monocytes (Smith et al., 2003), and
CD47 expressed on T cells was reported to inhibit mat-
uration and IL-12 production of human monocyte-de-
rived DC by interaction with SIRPa (Latour et al., 2001).
The mechanism by which ITIM-containing receptors
such as SIRP1a mediate their inhibitory effects have
been only partially characterized (Wu et al., 2000).
SIRP1a becomes phosphorylated upon binding to
CD47. This mediates recruitment and activation of Src
homology-containing phosphotyrosine phosphatase
(SHP) 1 and 2 that in turn dephosphorylates specific pro-
tein substrates. Overexpression of SIRP1awas reported
to inhibit TNF-a-induced activation of nuclear factor
(NF)-kB in fibroblasts (Neznanov et al., 2003), apparently
by inhibiting the activation of phosphoinositide 3-kinase
(PI3-K). The critical role of NF-kB in DC activation and IL-
12 production is well established (Murphy et al., 1995)
and may indicate a way how CD47-expressing erythro-
cytes control the maturation and IL-12 production of
SIRP1a-expressing slanDC.
Blocking of proinflammatory cells circulating in the
blood appears as a new important function of erythro-
cytes. However, under certain conditions such as bacte-
rial sepsis, this inhibition may not be complete, and es-
pecially septic patients with elevated systemic TNF-
a levels have a particularly poor prognosis (Casey
et al., 1993). Interestingly, serum IL-12 levels were nor-
mal in these patients. This is compatible with our finding
of a complete erythrocyte-mediated inhibition of IL-12
production by slanDC while their TNF-a production in re-
sponse to LPS stimulation is only partially blocked.
In addition to limiting the pathological effects of high
serum LPS levels as in sepsis, the impact of erythro-
cytes on slanDC may be critical when small amounts
of LPS derived from gram-negative E. coli of the intesti-
nal tract enter the systemic circulation. This occurs by
mucosal damage, for example after local intestinal hy-
poperfusion due to infarction resulting from atheroscle-
rosis or hemodynamic shock. Specifically, in patients
undergoing stem cell transplantation, it is suggested
that the prior conditioning regimen (chemotherapy, irra-
diation) allows an access of endotoxin to the systemic
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775circulation. This is regarded as an important trigger of
a subsequent graft versus host disease (Hill et al., 1997).
The control of the proinflammatory activity of slanDC
might be lost when these cells migrate into tissues
where they become activated by bacterial antigens
such as in inflammatory bowel disease. Recently,
slanDC were identified in the gut mucosa of patients
with active Crohn’s disease (de Baey et al., 2003). In ad-
dition, we demonstrate the presence of a high number of
slanDC in psoriasis vulgaris and rheumatoid arthritis,
which like Crohn’s disease are characterized by a strong
Th1-dominated inflammatory immune response. In light
of the recent therapeutic and experimental evidence
that local TNF-a- and IL-12-producing cells are central
to the clinical activity of psoriasis vulgaris (Kauffman
et al., 2004; Chaudhari et al., 2001), rheumatoid arthritis
(Elliott et al., 1994; Morita et al., 1998), and Crohn’s dis-
ease (Mannon et al., 2004; Targan et al., 1997), one may
speculate that slanDC are of critical pathogenic impor-
tance in these diseases.
Taken together, we have shown that proinflammatory
slanDC in the absence of an inhibitory signal rapidly ma-
ture and become high-level IL-12-producing cells in re-
sponse to TLR stimulation or CD40L. CD47 expressed
by erythrocytes and its ligand, the inhibitory molecule
SIRPa, can control the activation of slanDC. Given the
proinflammatory capacity of slanDC, their high fre-
quency in Th1-dominated inflammatory diseases, and
their stringent control of maturation, our data suggest
that these cells may be of great relevance for the pro-
gramming of Th1 cells and the activation of NK cells in
host defense against pathogens and tumors as well as
in the development of autoimmune diseases and chronic
forms of allergy.
Experimental Procedures
Cell Preparations and Cell Culture
PBMC were prepared by Ficoll gradient centrifugation. SlanDC were
isolated as previously described (Scha¨kel et al., 1998). PBMC were
incubated with 1:60 diluted M-DC8 supernatant of the M-DC8 hy-
bridoma that has been raised in our laboratory (1 ml/1 3 108
PBMC, stock 10 mg/ml) for 15 min at 4ºC, washed, and incubated
with anti-mouse IgM microbeads 10 ml/13 108 PBMC (Miltenyi, Ber-
gisch Gladbach, Germany). SlanDC as well as other cell populations
were sorted on two columns via the autoMACS (purity > 95%) (Mil-
tenyi). For complete depletion of slanDC from M-DC8-labeled
PBMC, a specific depletion program was run on the autoMACS.
PBMC without M-DC8 labeling were subjected to MACS sorting as
a control. BDCA-1+ (CD1c+) DC were isolated after purifying the
slanDC according to the manufacturer’s recommendation (Miltenyi).
Monocytes were isolated either by positive enrichment by CD14
beads or by a negative selection strategy giving the same ELISA re-
sults (Miltenyi). Untouched CD4+ CD45RA+ T cells were prepared
from umbilical cord blood by a CD4-T cell isolation kit supplemented
with CD45RO beads (Miltenyi). For the isolation of myeloid CD16+
cells or of CD14+/CD16+ cells, PBMC were first depleted of CD56+
NK cells followed by magnetic selection with anti-CD16 or anti-
CD14 and anti-CD16 beads, respectively (Miltenyi). The cell medium
was RPMI 1640 medium containing 10% human AB serum (CCPRO,
Neustadt, Germany), 2 mM L-glutamine, 1% nonessential amino
acids, 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom
AG, Berlin, Germany). DC were stimulated with the following TLR ag-
onists: LPS (E. coli 026:B6, Sigma, Deisenhofen, Germany), R848,
poly I:C, and Pam3CSK4 (InvivoGen, Toulouse, France). For TRIF-in-
hibition, resveratrol (50 mM, Sigma) was added directly to freshly
prepared DC followed by LPS-stimulation after 6 hr. IFN-g (PBH,
Hannover, Germany) was used at 100 ng/ml.Cells were seeded in 24-well (1 3 106/1 ml/well) (Greiner, Fricken-
hausen, Germany), 96-well (2 3 105/200 ml/well), or 384-well (0.5 3
105/100 ml/well) polystyrene plates (both Nunc, Wiesbaden, Ger-
many). In some experiments, cells were cultured in 1 ml teflon bea-
ker (Savillex, MN).
Cytokine Production by PBMC, DC, and Monocytes
For intracytoplasmic IL-12p40 staining, cells were stimulated in the
presence of 1 mg/ml brefeldin A (Sigma) to inhibit cytokine secretion.
After 18 or 24 hr, cells were harvested, stained for cell-surface
markers as indicated, fixed with fresh ice-cold 4% paraformalde-
hyde, and permeabilized with 0.1% saponin in PBS containing 1%
FCS. 1 3 106 cells were stained in a final volume of 20 ml containing
0.1 mg anti-IL-12p40-PE (clone C11.5) (BD Pharmingen, La Jolla, CA).
Secreted IL-12p70, IL12p40, TNF-a, IL-1b, and IL-6 were determined
in cell-free supernatants by ELISA (BD Pharmingen). For CD40 stim-
ulation, a human CD40L-transfected NIH3T3 fibroblast cell line was
employed (a kind gift from J.L. Schultze, University of Cologne, Ger-
many) and used after irradiation (96 Gy) at a density of 43 104/200 ml/
well. In initial control experiments, untransfected fibroblasts did not
induce cytokine production. Erythrocytes were washed and cocul-
tured with PBMC or slanDC at a ratio of 1:1000. When indicated,
the mAb OX118 (10 mg/ml) (Brooke et al., 2004) was added. To de-
plete erythrocytes prior to stimulation with LPS and/or IFN-g, cul-
tures were first subjected to Ficoll gradient centrifugation. Control
cultures were treated in the same manner.
Cell-Surface Staining
Among PBMC, slanDC were identified by staining with M-DC8 hy-
bridoma supernatant at a dilution of 1:20, followed by FITC-/PE-con-
jugated mouse IgM-specific goat F(ab0)2 (Beckman Coulter, Krefeld,
Germany). CD1c+ DC were identified among cultured PBMC by neg-
ative staining by means of mAb specific for 6-sulfo LacNAc (mAb M-
DC8), C5aR FITC (clone HC5aRZ1, a kind gift from J. Zwirner, Go¨ttin-
gen, Germany), CD3, CD14, CD16, CD19, CD34, as well as CD56 (all
FITC or PE labeled) and by positive staining for HLA-DR (PerCP) and
CD11c (APC). Additional antibodies were as follows: anti-CD11b PE,
anti-CD32 F, anti-33 PE, anti-CD40 FITC, anti-CD45RA PE, anti-
CD45RO PE, anti-CD62L PE, anti-CD64 F, anti-CD80 PE, anti-
CD83 PE, anti-CD86 FITC, and anti-C3aR FITC (clone HC3aRZ1,
a kind gift from J. Zwirner, Go¨ttingen, Germany). All mAbs were
from BD Pharmingen unless otherwise stated. Flow cytometric anal-
ysis was performed on a FACScan and FACScalibur (Becton Dickin-
son, Heidelberg, Germany).
T Cell Proliferation and Differentiation
CD4+ CD45RA+ allogeneic cord blood T cells (13 105) were added to
graded numbers of freshly isolated or 6 hr precultured slanDC in 96-
well round-bottom microtiter plates (Nunc). Proliferation of T cells
was determined after 4 days after a 16 hr pulse with [3H]thymidine
1 mCi/well (Hartmann Analytic, Braunschweig, Germany). Results
are expressed as mean cpm of triplicate cultures. For T cell pro-
gramming, slanDC and naive cord blood T cells were cocultured at
a ratio of 1:10. After 10–14 days, cells (1 3 106/ml) were stimulated
for 24 hr with ionomycin 1 mg/ml and phorbol 12-myristate 13-ace-
tate (PMA) 10 ng/ml (both from Sigma). 24 hr later, cell supernatants
were harvested and cytokine production was quantified by ELISA
(BD Pharmingen). For detection of intracytoplasmic cytokines, cells
were stimulated for 6 hr with ionomycin (1 mg/ml) and PMA (50 ng/
ml). Brefeldin A (Sigma, 10 mg/ml) was added for the last 4 hr. Cells
were fixed and permeabilized as described above and stained
with FITC-labeled IFN-g-specific and PE-labeled IL-4-specific
monoclonal antibodies (BD Pharmingen).
Preparation and Treatment Erythrocytes
Erythrocytes were freshly prepared by centrifugation of autologous
heparinized blood samples at 200 3 g for 10 min. The platelet-rich
plasma and leukocytes were removed and the pelleted erythrocytes
were washed three times in PBS to deplete serum proteins and re-
suspended in PBS at 50% hematocrit. Erythrocyte CD47 interaction
with cognate ligands was inhibited by prior incubation of the eryth-
rocytes with 40 mg/ml CD47-Fab (clone B6H12) (Latour et al., 2001).
In one series of experiments, the effect of anti-CD47 was compared
with that of an anti-CR1 (CD35) mAb (Pharmingen). The antioxidant
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776system of erythrocytes was blocked by the catalase inhibitor amino-
triazole at 50 mM and 0.4 mM H2O2 for 1 hr at 37ºC. Erythrocyte glu-
thatione peroxidase was blocked by treating the erythrocytes with
0.2 mM mercaptosuccinate for 1 hr at 37ºC. In some experiments,
erythrocytes were separated from DC by a porous membrane (filter
pore size 4 mm, Millipore, Schwalbach, Germany).
Immunohistochemistry and Immunofluorescence Analysis
Tissue samples that were obtained during diagnostic procedures
with the informed consent of the patient of psoriasis vulgaris-af-
fected skin and of rheumatoid arthritis-affected synovia were fixed
in 4% paraformaldehyde overnight, dehydrated, and embedded in
paraffin. Paraffin-embedded tissues were cut into 2–5 mm sections
and rehydrated. Antigen retrieval was performed by boiling the sec-
tions in sodium citrate (pH 7.0). The primary antibodies anti-CD68 (5
mg/ml, KP1, Dako Cytomation, Freiburg, Germany) and DD2 (1:50 hy-
bridoma supernatant) were applied for 1 hr at room temperature. Af-
ter washing, secondary antibody (biotinylated goat anti-Mouse Ig;
Vector Laboratories, Burlingame, CA) was applied. Endogenous
peroxidase was depleted after the binding of the secondary anti-
body by means of 0.5% (v/v) H2O2 in methanol. Streptavidin-horse-
radish peroxidase conjugate (Zymed, South San Francisco, CA) was
applied to the tissue sections, and antibody binding was detected
with the peroxidase substrate DAB (3,30-diaminobenzidine tablet
sets, 0.7 mg/ml; Sigma) according to the manufacturer’s protocol.
All sections were counterstained with Mayer’s hematoxylin (Merck).
Secondary antibodies for double immunofluorescence analysis
were anti-mouse IgM-specific goat F(ab´)2 -Alexa 488 and anti-
mouse IgG-specific goat F(ab´)2-Alexa 568 (Molecular Probes Invitro-
gen, Karlsruhe, Germany). Stained sections were observed with
a Zeiss Axiophot microscope.
Supplemental Data
The one Supplemental Figure can be found with this article online at
http://www.immunity.com/cgi/content/full/24/6/767/DC1/.
Acknowledgments
We thank Colleen Schmitz and Michael Bachmann for critical read-
ing of the manuscript. This work was supported by the Medical Fac-
ulty, Technische Universita¨t Dresden. The authors declare that they
have no competing financial interest.
Received: November 9, 2005
Revised: February 21, 2006
Accepted: March 15, 2006
Published: June 20, 2006
References
Aoshiba, K., Nakajima, Y., Yasui, S., Tamaoki, J., and Nagai, A.
(1999). Red blood cells inhibit apoptosis of human neutrophils.
Blood 93, 4006–4010.
Arosa, F.A., Pereira, C.F., and Fonseca, A.M. (2004). Red blood cells
as modulators of T cell growth and survival. Curr. Pharm. Des. 10,
191–201.
Brooke, G., Holbrook, J.D., Brown, M.H., and Barclay, A.N. (2004).
Human lymphocytes interact directly with CD47 through a novel
member of the signal regulatory protein (SIRP) family. J. Immunol.
173, 2562–2570.
Casey, L.C., Balk, R.A., and Bone, R.C. (1993). Plasma cytokine and
endotoxin levels correlate with survival in patients with the sepsis
syndrome. Ann. Intern. Med. 119, 771–778.
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., and
Gottlieb, A. (2001). Efficacy and safety of infliximab monotherapy
for plaque-type psoriasis: a randomised trial. Lancet 357, 1842–
1847.
Cohen, J. (1995). IL-12 deaths: explanation and a puzzle. Science
270, 908.
de Baey, A., Mende, I., Baretton, G., Greiner, A., Hartl, W.H.,
Baeuerle, P.A., and Diepolder, H.M. (2003). A subset of human den-
dritic cells in the T cell area of mucosa-associated lymphoid tissuewith a high potential to produce TNF-alpha. J. Immunol. 170,
5089–5094.
Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C.,
Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H.,
et al. (1994). Randomised double-blind comparison of chimeric
monoclonal antibody to tumour necrosis factor alpha (cA2) versus
placebo in rheumatoid arthritis. Lancet 344, 1105–1110.
Fonseca, A.M., Porto, G., Uchida, K., and Arosa, F.A. (2001). Red
blood cells inhibit activation-induced cell death and oxidative stress
in human peripheral blood T lymphocytes. Blood 97, 3152–3160.
Fonseca, A.M., Pereira, C.F., Porto, G., and Arosa, F.A. (2003). Red
blood cells promote survival and cell cycle progression of human
peripheral blood T cells independently of CD58/LFA-3 and heme
compounds. Cell. Immunol. 224, 17–28.
Gately, M.K., Renzetti, L.M., Magram, J., Stern, A.S., Adorini, L., Gu-
bler, U., and Presky, D.H. (1998). The interleukin-12/interleukin-12-
receptor system: role in normal and pathologic immune responses.
Annu. Rev. Immunol. 16, 495–521.
Hill, G.R., Crawford, J.M., Cooke, K.R., Brinson, Y.S., Pan, L., and
Ferrara, J.L.M. (1997). Total body irradiation and acute graft-ver-
sus-host disease: the role of gastrointestinal damage and inflamma-
tory cytokines. Blood 90, 3204–3213.
Kauffman, C.L., Aria, N., Toichi, E., McCormick, T.S., Cooper, K.D.,
Gottlieb, A.B., Everitt, D.E., Frederick, B., Zhu, Y., Graham, M.A.,
et al. (2004). A phase I study evaluating the safety, pharmacokinet-
ics, and clinical response of a human IL-12 p40 antibody in subjects
with plaque psoriasis. J. Invest. Dermatol. 123, 1037–1044.
Kharitonenkov, A., Chen, Z., Sures, I., Wang, H., Schilling, J., and Ull-
rich, A. (1997). A family of proteins that inhibit signalling through ty-
rosine kinase receptors. Nature 386, 181–186.
Latour, S., Tanaka, H., Demeure, C., Mateo, V., Rubio, M., Brown,
E.J., Maliszewski, C., Lindberg, F.P., Oldenborg, A., Ullrich, A.,
et al. (2001). Bidirectional negative regulation of human T and den-
dritic cells by CD47 and its cognate receptor signal-regulator pro-
tein-alpha: down-regulation of IL-12 responsiveness and inhibition
of dendritic cell activation. J. Immunol. 167, 2547–2554.
Leonard, J.P., Sherman, M.L., Fisher, G.L., Buchanan, L.J., Larsen,
G., Atkins, M.B., Sosman, J.A., Dutcher, J.P., Vogelzang, N.J., and
Ryan, J.L. (1997). Effects of single-dose interleukin-12 exposure
on interleukin-12-associated toxicity and interferon-gamma produc-
tion. Blood 90, 2541–2548.
Ma, X., and Trinchieri, G. (2001). Regulation of interleukin-12 produc-
tion in antigen-presenting cells. Adv. Immunol. 79, 55–92.
Mannon, P.J., Fuss, I.J., Mayer, L., Elson, C.O., Sandborn, W.J.,
Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R.L.,
et al. (2004). Anti-interleukin-12 antibody for active Crohn’s disease.
N. Engl. J. Med. 351, 2069–2079.
Morita, Y., Yamamura, M., Nishida, K., Harada, S., Okamoto, H., In-
oue, H., Ohmoto, Y., Modlin, R.L., and Makino, H. (1998). Expression
of interleukin-12 in synovial tissue from patients with rheumatoid ar-
thritis. Arthritis Rheum. 41, 306–314.
Murphy, T.L., Cleveland, M.G., Kulesza, P., Magram, J., and Murphy,
K.M. (1995). Regulation of interleukin 12 p40 expression through an
NF-kappa B half-site. Mol. Cell. Biol. 15, 5258–5267.
Neznanov, N., Neznanova, L., Kondratov, R.V., Burdelya, L., Kandel,
E.S., O’Rourke, D.M., Ullrich, A., and Gudkov, A.V. (2003). Dominant
negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-
1) inhibits tumor necrosis factor-mediated apoptosis by activation of
NF-kappa B. J. Biol. Chem. 278, 3809–3815.
O’Doherty, U., Peng, M., Gezelter, S., Swiggard, W.J., Betjes, M.,
Bhardwaj, N., and Steinman, R.M. (1994). Human blood contains
two subsets of dendritic cells, one immunologically mature and
the other immature. Immunology 82, 487–493.
Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lagenaur, C.F., Gre-
sham, H.D., and Lindberg, F.P. (2000). Role of CD47 as a marker of
self on red blood cells. Science 288, 2051–2054.
Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X.,
Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998). Defective
LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in
Tlr4 gene. Science 282, 2085–2088.
IL-12-Producing DC Are Controlled by Erythrocytes
777Portielje, J.E., Gratama, J.W., van Ojik, H.H., Stoter, G., and Kruit,
W.H. (2003). IL-12: a promising adjuvant for cancer vaccination.
Cancer Immunol. Immunother. 52, 133–144.
Randolph, G.J., Beaulieu, S., Lebecque, S., Steinman, R.M., and
Muller, W.A. (1998). Differentiation of monocytes into dendritic cells
in a model of transendothelial trafficking. Science 282, 480–483.
Randolph, G.J., Sanchez-Schmitz, G., Liebman, R.M., and Scha¨kel,
K. (2002). The CD16(+) (FcgammaRIII(+)) subset of human monocytes
preferentially becomes migratory dendritic cells in a model tissue
setting. J. Exp. Med. 196, 517–527.
Robertson, M.J., Soiffer, R.J., Wolf, S.F., Manley, T.J., Donahue, C.,
Young, D., Herrmann, S.H., and Ritz, J. (1992). Response of human
natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic
activity and proliferation of NK cells are differentially regulated by
NKSF. J. Exp. Med. 175, 779–788.
Scha¨kel, K., Mayer, E., Federle, C., Schmitz, M., Riethmuller, G., and
Rieber, E.P. (1998). A novel dendritic cell population in human
blood: one-step immunomagnetic isolation by a specific mAb (M-DC8)
and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol.
28, 4084–4093.
Scha¨kel, K., Kannagi, R., Kniep, B., Goto, Y., Mitsuoka, C., Zwirner,
J., Soruri, A., von Kietzell, M., and Rieber, E. (2002). 6-Sulfo LacNAc,
a novel carbohydrate modification of PSGL-1, defines an inflamma-
tory type of human dendritic cells. Immunity 17, 289–301.
Schmitz, M., Zhao, S., Scha¨kel, K., Bornhauser, M., Ockert, D., and
Rieber, E.P. (2002). Native human blood dendritic cells as potent ef-
fectors in antibody-dependent cellular cytotoxicity. Blood 100,
1502–1504.
Schmitz, M., Zhao, S., Deuse, Y., Scha¨kel, K., Wehner, R., Wohner,
H., Holig, K., Wienforth, F., Kiessling, A., Bornhauser, M., et al.
(2005). Tumoricidal potential of native blood dendritic cells: direct
tumor cell killing and activation of NK cell-mediated cytotoxicity. J.
Immunol. 174, 4127–4134.
Seiffert, M., Cant, C., Chen, Z., Rappold, I., Brugger, W., Kanz, L.,
Brown, E.J., Ullrich, A., and Buhring, H.-J. (1999). Human signal-reg-
ulatory protein is expressed on normal, but not on subsets of leuke-
mic myeloid cells and mediates cellular adhesion involving its coun-
terreceptor CD47. Blood 94, 3633–3643.
Smith, R.E., Patel, V., Seatter, S.D., Deehan, M.R., Brown, M.H.,
Brooke, G.P., Goodridge, H.S., Howard, C.J., Rigley, K.P., Harnett,
W., and Harnett, M.M. (2003). A novel MyD-1 (SIRP-1alpha) sig-
naling pathway that inhibits LPS-induced TNFalpha production by
monocytes. Blood 102, 2532–2540.
Targan, S.R., Hanauer, S.B., van Deventer, S.J.H., Mayer, L., Pres-
ent, D.H., Braakman, T., DeWoody, K.L., Schaible, T.F., Rutgeerts,
P.J., and The Crohn’s Disease cA2 Study Group (1997). A short-
term study of chimeric monoclonal antibody cA2 to tumor necrosis
factor {alpha} for Crohn’s disease. N. Engl. J. Med. 337, 1029–1036.
Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resis-
tance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146.
Weighardt, H., Jusek, G., Mages, J., Lang, R., Hoebe, K., Beutler, B.,
and Holzmann, B. (2004). Identification of a TLR4- and TRIF-depen-
dent activation program of dendritic cells. Eur. J. Immunol. 34,
558–564.
Wu, C.J., Chen, Z., Ullrich, A., Greene, M.I., and O’Rourke, D.M.
(2000). Inhibition of EGFR-mediated phosphoinositide-3-OH kinase
(PI3-K) signaling and glioblastoma phenotype by signal-regulatory
proteins (SIRPs). Oncogene 19, 3999–4010.
Youn, H.S., Lee, J.Y., Fitzgerald, K.A., Young, H.A., Akira, S., and
Hwang, D.H. (2005). Specific inhibition of MyD88-independent sig-
naling pathways of TLR3 and TLR4 by resveratrol: molecular targets
are TBK1 and RIP1 in TRIF complex. J. Immunol. 175, 3339–3346.
